European Pharmaceutical Review

NOVEMBER 2, 2023

Sustainable biosimilar competition in Europe: can it be achieved? Stelara biosimilars in the US market The first Stelara biosimilars are expected to enter the US market in 2025. “We US sales of Stelara totalled $6.4 However, he did note that Stelara does have a composition of matter patent expiry in mid-2024 in Europe.

Food and Drug Administration 98

Food and Drug Administration FDA Side effects Safety 98

Pharmaceutical Technology

JUNE 7, 2023

Mounjaro’s approval for obesity, particularly in the US and EU markets, means the drug is entering a significantly large market where it will have direct competition from Novo Nordisk’s Wegovy (semaglutide), which is currently the leading glucagon-like peptide-1 (GLP-1) therapy approved for obesity by both the FDA and EMA.

Leads 98

Leads Marketing FDA Sales 98

Pharmaceutical Technology

JANUARY 30, 2023

According to GlobalData’s Drugs database, there were 22 prophylactic vaccines in development for COVID-19 with sales forecasts available in H2 2022. According to GlobalData’s Drugs database, there were 22 prophylactic vaccines in development for COVID-19 with sales forecasts available in H2 2022.

Sales 52

Sales Leads Competition Medicine 52

PM360

SEPTEMBER 21, 2023

They do not have biosimilar or generic competition available in the market. Over the next few weeks, manufacturers will submit a range of clinical, marketing, sales, pricing, and patient data, and then meet with CMS to discuss submissions later this fall. They do not qualify for any exemption (e.g.,

Manufacturing 111

Manufacturing Marketing Competition Physicians 111

Pharmaceutical Technology

OCTOBER 31, 2022

Two categories of novel therapies stand out: cell therapies and therapies with novel MOAs, with new products in each category being forecast to launch between 2023 and 2025. These are forecast to contribute significantly towards sales in the OA market in 2031, accounting for 10% and 14.2% of the 7MM sales, respectively.

Marketing 59

Marketing Sales Patients Competition 59

Clarivate

JANUARY 23, 2024

forecast peak sales per asset versus the cost of developing an asset or an output measure such as the number of global first world launches). In addition, R&D productivity analyses are in some way associated with actual or future launches or a consequence of the launch, such as resulting sales.

Pharma 52

Pharma Sales Consulting Pharmaceutical 52

Clarivate

AUGUST 27, 2024

and ramped up sales of PFA systems in Europe. Based on brisk uptake in the latter half of the first quarter, it appeared that PFA would account for at least 30% of the ablation market and $1 billion in sales by the end of 2024. Since the FDA’s approval of the first pulsed field ablation (PFA) system in the U.S. s Farapulse.

Marketing 52

Marketing Competition FDA Electronics 52

pharmaphorum

JANUARY 10, 2023

Approximately 30% of global data volume is generated by the healthcare industry and it will continue to expand with a compound annual growth rate predicted to reach 36% by 2025, according to research by RBC Capital Markets. If you have to wait to extract meaning from your data then you won’t be competitive enough. “A

Marketing 98

Marketing Pharma Healthcare Healthcare 98

Pharmaceutical Technology

JULY 21, 2022

Pharma giant AstraZeneca also plans to make its supply chain carbon-negative by 2030; to reduce its Scope 1 emissions by 20%, Scope 2 emissions by 95%, and Scope 3 emissions by 25% per $1m of sales by 2025. Access to medication. Improving access could save ten million lives each year, four million in Africa and Southeast Asia.

Government 52

Government Healthcare Healthcare Pharma 52

Clarivate

DECEMBER 7, 2021

The previously clear lines between sectors are blurring and the competitive set is widening. Indeed, millennial consumers are expected to drive 50% of luxury goods purchases by 2025. [1]. 1] The Drum, “Millennials and Gen Z to make up 50% of luxury spending by 2025” , January 2021. [2] There are other areas of consideration too.

Professional Services 95

Professional Services Management Competition Sales 95

pharmaphorum

SEPTEMBER 11, 2022

Analysts at Mizuho have suggested that competition from BMS’ drug could trim Otezla’s 2025 sales from $3 billion to $2 billion, although Amgen is attempting to defend its product by expanded the label of the drug to include mild psoriasis. Otezla was acquired by Amgen for $13.4

FDA 52

FDA Marketing Patients Sales 52

PM360

JULY 13, 2023

billion by 2025, growing at a compound annual growth rate of 6.7%. Market research and competitive analysis Conduct thorough market research to understand the existing solutions and identify your competition. The global healthcare IT market was valued at $280.3 billion in 2020 and is expected to reach $381.7

Healthcare 98

Healthcare Healthcare Consulting Healthcare Provider 98

pharmaphorum

JULY 15, 2022

At the time, she said, “companies have to respect our competition rules and procedures. If it proves effective in the trial, the UK has said it could roll testing out to one million people in 2024 and 2025.

Competition 52

Competition Marketing Medicine Sales 52

Med Device Careers

JANUARY 3, 2022

and the global IC device market is projected to reach over $20 billion dollars by 2025. The career opportunities are highly desirable, competitive, and rewarding with starting U.S. Regarding the job market and potential for career growth, healthcare makes up over 11 percent of the workforce in the U.S.

Specialization 52

Specialization Medical Engineering Healthcare 52

Healthcare Success

OCTOBER 11, 2022

Attract more affluent healthcare consumers, increase patient volume, and reach your premium product or service sales goals when you implement these marketing strategies. Consider your target audience when writing content for sales, social media, and other resources, and use words, phrases, and storylines that resonate with their values.

Healthcare 62

Healthcare Healthcare Marketing Retail 62

PM360

SEPTEMBER 28, 2022

Drug manufacturers should prepare formulary access and contracting strategies that consider the implications of the IRA through 2025 and beyond. What to watch: Plans positioning for the future: Plans will submit bids for 2025 under the redesigned Part D benefit. Maximum patient Part D out-of-pocket set at $2,000.

Government 97

Government Manufacturing Prescription Competition 97

Celeritas

NOVEMBER 7, 2022

billion by 2025. The provision of a competitive advantage over other dairy suppliers also plays a major role in the considerations. Automated cleaning systems improve hygiene to lower the risk of infection and facilitate the ease of access for waste removal machinery. The drone services market size is expected to grow to $63.6

Networking 52

Networking Pharmaceutical products Management Transportation 52

Clarivate

DECEMBER 14, 2023

With analysts estimating that obesity drug sales could top $100 billion annually , concerns over the financial hit is likely why plans covering 30% of lives do not reimburse Wegovy, per Clarivate Fingertip Analytics data. If 2025 starts with another split Congress or total Republican control, subsidies face a much tougher road for renewal.

Marketing 52

Marketing Healthcare Healthcare Insurance 52